Takeda invests in stem cells with new facility, jobs

Mar 01, 2018

Japan-based Takeda will create 70 new rolls as well as invest $30.5 million to construct a new regenerative medicine facility at its existing site in Dublin, Ireland.

The new standalone facility will dedicated to manufacturing a novel stem cell therapy. The Dublin site will be the first site to introduce this new technology platform to Takeda’s manufacturing network.

The drugmaker intends for the modular cell therapy operation to be up and running by 2021.

Read the Irish Independent coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments